Oramed Pharmaceuticals, the developer of the Oravax oral COVID-19 vaccine candidate, has announced a partnership with Mexico’s Genomma Lab Internacional to help fast-track a Phase II clinical trial and gain emergency use authorization in the Latin American country.
Only about 58% of Mexico’s population has been jabbed with one dose of a coronavirus vaccine, averaging around 4,500 new cases per day.
Comments are closed.